7 completed, 5 recruiting, 2 terminated, 2 unknown. 5 Phase 4, 3 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Unknown 2, Completed 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Certolizumab: new trials by email Literature Review of Certolizumab trials Research Report on Certolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Placebo, Nipocalimab, Certolizumab - Arthritis, Rheumatoid | Phase 2 | Completed | Janssen Research & Development, LLC | 103 | 2023-08-15 | 2025-10-16 |
| Stand UP to Rheumatoid Arthritis (SUPRA) TNFi, Anti-IL6, JAKi - Rheumatoid Arthritis | Not applicable | Recruiting | Marie Hudson, MD | 75 | 2023-02-01 | 2026-02-03 |
| Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery Cisplatin, Pemetrexed, Gemcitabine - Lung Cancer, Lung Cancer Stage II | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2022-10-19 | 2026-10-02 |
| COVID-19 VaccinE Response in Rheumatology Patients Upadacitinib, Abatacept, Secukinumab - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 4 | Completed | Jeffrey Curtis | 841 | 2021-11-15 | 2025-05-02 |
| Ultrasound Enthesitis Response in Psoriatic Arthritis adalimumab, Certolizumab, Etanercept - Psoriatic Arthritis, Psoriasis | Completed | Belfast Health and Social Care Trust | 80 | 2019-02-14 | 2022-02-07 | |
| CHronic Nonbacterial Osteomyelitis International Registry Methotrexate, Sulfasalazine, Leflunomide - Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis | Recruiting | Seattle Children's Hospital | 2000 | 2018-08-01 | 2024-07-30 | |
| Lipids, Inflammation, and CV Risk in RA Certolizumab - Rheumatoid Arthritis, Cardiovascular Disease | Completed | Brigham and Women's Hospital | 74 | 2016-10-17 | 2026-01-21 | |
| Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis Anti-TNF suspended perioperatively, Anti-TNFα continued perioperatively - Rheumatoid Arthritis | Phase 4 | Unknown | CHU de Quebec-Universite Laval | 660 | 2015-07-01 | 2018-07-18 |
| Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas Certolizumab, cisplatin, pemetrexed - Stage IV Lung Adenocarcinoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 30 | 2014-04-15 | 2023-01-26 |
| Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Etanercept, Adalimumab, Certolizumab - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 4 | Unknown | Jagiellonian University | 100 | 2013-06-01 | 2014-05-07 |
| Cimzia Versus Mesalamine for Crohn's Recurrence Cimzia, Mesalamine - Crohn's Disease | Phase 4 | Terminated | Milton S. Hershey Medical Center | 10 | 2013-02-01 | 2018-01-12 |
| EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment Certolizumab - Crohns Disease | Terminated | Baylor College of Medicine | 1 | 2011-06-01 | 2016-02-19 | |
| Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA) Certolizumab - Rheumatoid Arthritis | Completed | University of Rochester | 5 | 2010-10-01 | 2015-09-21 | |
| Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response Methotrexate, Abatacept, Adalimumab - Rheumatoid Arthritis | Phase 3 | Recruiting | University of Nebraska | 400 | 2007-12-10 | 2026-06-17 |
| Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs Biologic Agents - Rheumatoid Arthritis, Spondyloarthritis | Completed | Simon Krabbe | 7500 | 2006-01-01 | 2018-04-17 |
Arthritis, Rheumatoid (10) · Arthritis, Psoriatic (5) · Spondylarthritis (3) · Crohn Disease (2) · Psoriasis (2) · Spondylitis, Ankylosing (2) · Adenocarcinoma of Lung (1) · Arthritis, Juvenile (1) · Cardiovascular Diseases (1) · Chronic recurrent multifocal osteomyelitis (1) · Dermatitis, Atopic (1) · Dermatomyositis (1) · Giant Cell Arteritis (1) · Granulomatosis with Polyangiitis (1) · Hypertension (1)
Memorial Sloan Kettering Cancer Center (2) · Baylor College of Medicine (1) · Belfast Health and Social Care Trust (1) · Brigham and Women's Hospital (1) · CHU de Quebec-Universite Laval (1) · Jagiellonian University (1) · Janssen Research & Development, LLC (1) · Jeffrey Curtis (1) · Marie Hudson, MD (1) · Milton S. Hershey Medical Center (1) · NYU Langone Health (1) · Seattle Children's Hospital (1) · Simon Krabbe (1) · University of California, San Francisco (1) · University of Nebraska (1)
United States (12) · Canada (2) · Poland (2) · United Kingdom (2) · Argentina (1) · Germany (1) · Hungary (1)
Bincy P. Abraham, MD, MS (1) · Bogdan Batko, MD, PhD (1) · Christopher Ritchlin, MD / MPH (1) · David B Stewart, MD (1) · James R O'Dell, MD (1) · Jeffrey R Curtis, MD MS MPH (1) · Jonathan Samuels, MD (1) · Katherine P Liao, MD, MPH (1) · Madeleine Rooney, MD (1) · Marie Hudson, MD (1) · Merete L Hetland, DMSc (1) · Paul Paik (1) · Paul Paik, MD (1)
PMID 21884592, PMID 27586634, PMID 34888436, PMID 35657008, PMID 38686879, PMID 41781163, PMID 42832241
2023 (1), R01HL127118 (1)